Observation of the Efficacy and Safety of Paricalcitol and Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Maintenance Hemodialysis Patients
Objective To explore the effects of paricalcitol and cinacalcet in patients with secondary hyperparathyroidism undergoing maintenance hemodialysis.Methods From January 2022 to August 2023,72 patients with secondary hyperparathyroidism undergoing maintenance hemodialysis were selected from The Second Affiliated Hospital of Luohe Medical College.They were randomly divided into a reference group(36 cases,treated with paricalcitol)and an experimental group(36 cases,treated with paricalcitol combined with cinacalcet).Serum immunoreactive parathyroid hormone(iPTH),blood calcium,blood phosphorus,interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP),treatment efficacy,and adverse reactions were analyzed.Results After treatment,the levels of iPTH,blood calcium,and blood phosphorus in the experimental group were lower than those in the reference group,with statistically significant differences(P＜0.05).After treatment,the levels of IL-6,TNF-α,and hs-CRP in the experimental group were lower than those in the reference group,with statistically significant differences(P＜0.05).The treatment efficacy in the experimental group was higher than that in the reference group,with statistically significant differences(P＜0.05).The adverse reaction rate in the experimental group was lower than that in the reference group,with statistically significant differences(P＜0.05).Conclusion Paricalcitol combined with cinacalcet can inhibit the synthesis of parathyroid hormone,improve inflammatory status,enhance treatment efficacy,and reduce adverse reactions in the treatment of secondary hyperparathyroidism in maintenance hemodialysis patients,showing good clinical application value.
万方数据
维普
